


Supplementary 1. STROBE checklist.

	Item No	Recommendation	Page number	Line number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	2-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	26-52
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5	66-104
Objectives	3	State specific objectives, including any prespecified hypotheses	5	102-104
Methods				
Study design	4	Present key elements of study design early in the paper	6	108-126
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6	108-126
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6	108-126
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7	128-142
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7	144-161
Bias	9	Describe any efforts to address potential sources of bias	8	164-183
Study size	10	Explain how the study size was arrived at	NA	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7	144-161
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8	164-183
		(b) Describe any methods used to examine subgroups and interactions	NA	NA
		(c) Explain how missing data were addressed	NA	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA	NA
		(e) Describe any sensitivity analyses	8	185-188
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9	196-201
		(b) Give reasons for non-participation at each stage	Figure 1	Figure 1
		(c) Consider use of a flow diagram	Figure 1	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9	203-211

		(b) Indicate number of participants with missing data for each variable of interest	NA	NA
		(c) Summarise follow-up time (eg, average and total amount)	10	224-247
Outcome data	15*	Report numbers of outcome events or summary measures over time	10	224-247
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10	224-247
		(b) Report category boundaries when continuous variables were categorized	Table 1	Table 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10	250-261
Discussion				
Key results	18	Summarise key results with reference to study objectives	12	263-268
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13	317-325
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13	270-315
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13	270-315
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3	57-63

Supplementary 2. Directed acyclic graph (DAG) to represent the causal relationship between antibiotic treatment and patient mortality.



Footnote: Arrows indicate the direction of a causal relationship; for instance, the relationship “severity of underlying illnesses may cause increases in the probability of antibiotic-resistant infection” is represented by an arrow from “Severity of underlying illness” to “Type of infection (AMR or non-AMR)”.

Supplementary 3. Stata code used to calculate the stabilized inverse probability weights for the marginal structural model.

```

=====
* Analyses to adjust for pre-defined confounders, time-varying confounders, and immortal-time bias *
=====

clear all
set more off

* ----- *
* Data in wide format *
* ----- *
use "$analysisData/hai_acine_analysis_wide.dta", clear

* Outcome variable
tab inhosp, missing
gen y=(inhosp==1 & los_spc_dis<=30)
gen sens_y=((dcstatus==3 | dctype=="2" | inhosp==1) & los_spc_dis<=30)

/*
dcstatus==3; not improved
dctype==2; rejected treatment
*/

tab y sens_y
* Exposure groups
gen exp_atb=99
replace exp_atb=0 if (strmatch(cat_name, "cat_1")==1 | ///
    strmatch(cat_name, "cat_2")==1 | strmatch(cat_name, "cat_3")==1 | ///
    strmatch(cat_name, "cat_4")==1 | strmatch(cat_name, "cat_5")==1 | ///
    strmatch(cat_name, "cat_6")==1 | strmatch(cat_name, "cat_10")==1)
replace exp_atb=1 if (strmatch(cat_name, "cat_7")==1 | ///
    strmatch(cat_name, "cat_8")==1 | strmatch(cat_name, "cat_9")==1 | ///
    strmatch(cat_name, "cat_12")==1)
replace exp_atb=2 if (strmatch(cat_name, "cat_11")==1 | ///
    strmatch(cat_name, "cat_14")==1)
replace exp_atb=3 if (strmatch(cat_name, "cat_13")==1)
tab exp_atb, mi
tab y exp_atb, col

* IPW for t0
fp <los_adm_spc>: logit atbuse_cat0 ///
    i.MDR age i.gender_num ///
    prior_days_on_atb0 i.spc_year i.department0 ///
    i.adm_icu i.charlson_age <los_adm_spc>, or
predict ipw_deno_p1
replace ipw_deno_p1=1-ipw_deno_p1 if atbuse_cat0==0
logit atbuse_cat0
predict ipw_num_p1
replace ipw_num_p1=1-ipw_num_p1 if atbuse_cat0==0
gen ipw_p1=ipw_num_p1/ipw_deno_p1
count if ipw_p1==.
replace ipw_p1=1 if ipw_p1==.

*** Analysis: impact of ≥1 days of concordant treatment on 30-day mortality ***
preserve
* Note: if concordant then atbuse_cat0=1, otherwise 0
//gen atbuse_cat0_2=1-atbuse_cat0 if atbuse_cat0!=.
logit y i.atbuse_cat0 [pw=ipw_p1]
//margins atbuse_cat0_2
/*
-----
|           Delta-method
| Margin Std. Err.   z   P>|z|   [95% Conf. Interval]

```

```

-----+-----
atbuse_cat0 |
  0 | .4035512 .0220405 18.31 0.000 .3603526 .4467497
  1 | .3376714 .0239005 14.13 0.000 .2908272 .3845155
-----+-----

```

```

*/
qui logit y i.atbuse_cat0 [pw=ipw_p1]
margins, dydx(atbuse_cat0)
/*

```

```

-----+-----
|          Delta-method
| dy/dx Std. Err. z P>|z| [95% Conf. Interval]
-----+-----
1.atbuse_cat0 | -.0658798 .0325118 -2.03 0.043 -.1296018 -.0021578
-----+-----

```

```

*/
logit sens_y i.atbuse_cat0 [pw=ipw_p1]
margins atbuse_cat0
/*

```

```

-----+-----
|          Delta-method
| Margin Std. Err. z P>|z| [95% Conf. Interval]
-----+-----
atbuse_cat0 |
  0 | .6204345 .0223269 27.79 0.000 .5766746 .6641944
  1 | .58828 .0258206 22.78 0.000 .5376726 .6388874
-----+-----

```

```

*/
logit sens_y i.atbuse_cat0 [pw=ipw_p1]
/*

```

```

-----+-----
|          Delta-method
| dy/dx Std. Err. z P>|z| [95% Conf. Interval]
-----+-----
1.atbuse_cat0 | -.0321545 .0341349 -0.94 0.346 -.0990576 .0347487
-----+-----

```

```

*/
margins, dydx(atbuse_cat0)

```

restore

```

* IPW for t1
fp <los_adm_spc>, replace: logit atbuse_cat1 i.atbuse_cat0 i.vaso_use0##i.icu0 ///
    i.MDR age i.gender_num ///
    prior_days_on_atb0 i.spc_year i.department0 ///
    i.adm_icu i.charlson_age <los_adm_spc>, or
predict ipw_deno_p2
replace ipw_deno_p2=1-ipw_deno_p2 if atbuse_cat1==0
logit atbuse_cat1
predict ipw_num_p2
replace ipw_num_p2=1-ipw_num_p2 if atbuse_cat1==0
gen ipw_p2=ipw_num_p2/ipw_deno_p2
replace ipw_p2=1 if ipw_p2==.

```

```

* IPW for t2
fp <los_adm_spc>, replace: logit atbuse_cat2 i.atbuse_cat1 i.vaso_use1##i.icu1 ///
    i.MDR age i.gender_num ///
    prior_days_on_atb0 i.spc_year i.department0 ///
    i.adm_icu i.charlson_age <los_adm_spc>, or
predict ipw_deno_p3
replace ipw_deno_p3=1-ipw_deno_p3 if atbuse_cat2==0
logit atbuse_cat2
predict ipw_num_p3
replace ipw_num_p3=1-ipw_num_p3 if atbuse_cat2==0
gen ipw_p3=ipw_num_p3/ipw_deno_p3
replace ipw_p3=1 if ipw_p3==.

```

```

* Pooled ipw
gen sipw_tvc=(ipw_p1*ipw_p2*ipw_p3)
count if sipw_tvc==.
replace sipw_tvc=10 if sipw_tvc>10

*****
*** IPW for immortal-time (Survival) bias ***
*****

*** Step 1: clone ***
expand 3 if exp_atb!=0
count
bysort hn: gen n=_n
gen regimen=n
replace regimen=0 if exp_atb==0
tab regimen, mi
drop n

gen obs_full=(cat_name=="cat_1" | cat_name=="cat_4" | cat_name=="cat_5" | ///
               cat_name=="cat_7" | cat_name=="cat_10" | cat_name=="cat_11" | ///
               cat_name=="cat_12" | cat_name=="cat_13")
gen obs_mis1=(cat_name=="cat_2" | cat_name=="cat_6" | cat_name=="cat_8" | ///
              cat_name=="cat_14")
gen obs_mis2=(cat_name=="cat_3" | cat_name=="cat_9")

*** Step 2: artificial censor ***
* Censor obs that deviate from the 'assigned' regimen
gen censor=0
replace censor=1 if (obs_full==1 & exp_atb==regimen) //1=uncensor; 0=censor
replace censor=1 if (((exp_atb==regimen) | (exp_atb+1==regimen)) & obs_mis1==1)
replace censor=1 if (obs_mis2==1) & ((exp_atb==regimen) | (exp_atb+1==regimen)
|(exp_atb+2==regimen))
replace censor=1 if regimen==0

*** Step 3: IPW for censor ***
gen ipw_cen=.
* Probability of uncensored for those observed till t=2 is 1 hence IPW=1
replace ipw_cen=3 if obs_full==1 & censor==1
* Probability of uncensored for those survived till t=1
replace ipw_cen=3/2 if (cat_name=="cat_14") & (censor==1)
* Probability of uncensored for those survived >=0
replace ipw_cen=1 if (cat_name=="cat_9") & (censor==1)
* Probability of uncensored for exceptional cases
replace ipw_cen=3 if (cat_name=="cat_8") & (censor==1) & (regimen==exp_atb)
replace ipw_cen=0 if (cat_name=="cat_8") & (censor==1) & (regimen!=exp_atb)
* no weight for artificial censored obs
replace ipw_cen=0 if censor==0
* Probability of being uncensored for regimen=0
replace ipw_cen=1 if exp_atb==0 // because never artificial censored

*** Combine ipw for confounder and selection ***
gen total_ipw=ipw_cen*sipw_tvc

*** Final MSM with the total IPW ***
logit y i.regimen [pw=total_ipw], cluster(hn) or
margins regimen
/*

```

```

-----
|           Delta-method
|   Margin Std. Err.   z   P>|z|   [95% Conf. Interval]
-----+-----
regimen |
  0 |   .3974978   .038129   10.43   0.000   .3227664   .4722292
  1 |   .4274677   .0661823    6.46   0.000   .2977528   .5571826
  2 |   .5103964   .0620116    8.23   0.000   .388856   .6319368
  3 |   .4085445   .0249264   16.39   0.000   .3596895   .4573994
-----

```

```
*/
```

margins, dydx(regimen) ///difference between the margins
/*

```
-----+-----
```

	Delta-method					
	dy/dx	Std. Err.	z	P> z	[95% Conf. Interval]	
-----+-----						
regimen						
1	.0299699	.0763801	0.39	0.695	-.1197322	.1796721
2	.1128986	.072796	1.55	0.121	-.0297788	.2555761
3	.0110466	.0455538	0.24	0.808	-.0782371	.1003304

*/

*** Sensitivity analysis: final MSM with the total IPW ***

logit sens_y i.regimen [pw=total_ipw], cluster(hn) or
margins regimen

/*


```
-----+-----
```

	Delta-method					
	Margin	Std. Err.	z	P> z	[95% Conf. Interval]	
-----+-----						
regimen						
0	.646247	.0398024	16.24	0.000	.5682357	.7242583
1	.6315866	.065175	9.69	0.000	.5038459	.7593272
2	.6847273	.0631484	10.84	0.000	.5609588	.8084958
3	.6339658	.025017	25.34	0.000	.5849334	.6829982

*/

Supplementary 4. Diagnosis of the stabilized IPWs for assessing the exchangeability and positivity assumptions of the causal framework.

2.1. Distribution of stabilized IPWs used to adjust for confounders and immortal time bias in the model to estimate the marginal probability of 30-day mortality under no delays in concordant antibiotic treatment, one-day delay in concordant antibiotic treatment, two-day delay in concordant antibiotic treatment, and three or more days of delays in concordant antibiotic treatment groups.



The mean and standard deviation of the stabilized IPWs were 0.889 and 2.369, respectively. The minimum and maximum stabilized IPWs were 0 and 30 respectively. The proportion of stabilized IPWs that had a value more than 5 was 0.032.

2.2. Patient characteristics of the four treatment regimens in the weighted sample.

	No delays to concordant antibiotic treatment	1 day of delay to concordant antibiotic treatment	2 day of delay to concordant antibiotic treatment	At least 3 day of delay to concordant antibiotic treatment
Age (years)	55 (28-72)	57 (36-70)	48 (26-69)	54 (20-70)
Female gender	51%	49%	49%	38%
Multi-drug resistance	79%	85%	84%	74%
Age-adjusted CCI score on admission	2 (0-4)	3 (0-4)	2 (0-4)	2 (0-4)
Vasopressor prescribed on the day of blood specimen collected for culture	46%	51%	31%	32%
Admitted to ICU on the day of hospitalization	62%	66%	60%	45%
Admitted to ICU on the day of blood specimen collected for culture	67%	65%	58%	53%
Length of hospital stay since admission to blood specimen collected for culture date (days)	7 (5-15)	8 (5-16)	9 (5-17)	10 (6-17)
Days on antibiotic prior blood collection	7 (4-14)	6 (1-12)	8 (5-18)	8 (4-17)

Footnote: Age, CCI score, length of hospital stay since admission to blood collection date, and days on antibiotic prior blood specimen collection are median (IQR), and other data are n (%). ICU=intensive care unit. CCI=Charlson Comorbidity Index Score; defined using ICD10 scores.¹ Multidrug resistance is defined as non-susceptible to ≥ 1 agent in ≥ 3 antimicrobial categories.²

Supplementary 5. Estimated probability of observing detrimental outcome within 30 days post blood collection under each exposure group.

	Crude proportion of patients who developed detrimental outcome* within 30-days post blood collection	Expected proportion of patient with detrimental outcome* (95% CI) under each treatment regimen
No delays to concordant antibiotic treatment	58%	65% (57%-72%)
A one day of delay to concordant antibiotic treatment	82%	63% (50%-76%)
A two day of delay to concordant antibiotic treatment	67%	68% (56%-81%)
Three or more days of delays to concordant antibiotic treatment	50%	63% (58%-68%)

*Detrimental outcome was defined as died within the hospital, discharged without improvement, or rejected treatment within 30 days of blood collection.

Supplementary 6. The estimated effect of the four treatment regimens on 30-day in-hospital all-cause mortality and detrimental outcomes.

	Odds ratio for 30-day in-hospital all-cause mortality (95% CI)	Odds ratio for detrimental outcomes* (95% CI)
No delays to concordant antibiotic treatment	Reference group	Reference group
A one day of delay to concordant antibiotic treatment	1.1 (0.6-2.1)	0.9 (0.5-1.8)
A two day of delay to concordant antibiotic treatment	1.6 (0.9-2.8)	1.2 (0.6-2.3)
Three or more days of delays to concordant antibiotic treatment	1.0 (0.7-1.5)	0.9 (0.6-1.4)

*Detrimental outcome was defined as died within the hospital, discharged without improvement, or rejected treatment within 30 days of blood collection.

References

1. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol* 2004;57:1288-94.
2. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268-81.